Skip to main content

Table 3 Adverse events occurring in ≥4% of patients per agent

From: Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry

 

IFX (N = 890)

GLM (N = 530)

GLM-IV (N = 157)

Exposure (Total, Mean pt.yrs)

2714, 3.0

1077, 2.0

257, 1.6

SOC

N of Events

N of Patients

% of Patients

Rate/100 Pt-Yrs

N of Events

N of Patients

% of Patients

Rate/100 Pt-Yrs

N of Events

N of Patients

% of Patients

Rate/100 Pt-Yrs

Total

3017

547

61.5%

105

1212

357

67.4%

113

212

93

59.2%

82.6

Cardiac disorders

45

39

4.4%

1.56

20

16

3.0%

1.86

1

1

0.6%

0.39

Eye disorders

73

47

5.3%

2.53

25

15

2.8%

2.32

2

2

1.3%

0.78

Gastrointestinal disorders

193

112

12.6%

6.69

73

52

9.8%

6.78

12

7

4.5%

4.68

General disorders and administration site conditions

297

175

19.7%

10.3

169

148

27.9%

15.7

40

38

24.2%

15.6

Infections and infestations

689

275

30.9%

23.9

378

173

32.6%

35.1

62

36

22.9%

24.2

Injury, poisoning and procedural complications

178

108

12.1%

6.17

56

36

6.8%

5.2

17

11

7.0%

6.62

Investigations

7

58

6.5%

2.56

13

10

1.9%

1.21

5

4

2.5%

1.95

Musculoskeletal and connective tissue disorders

486

152

17.1%

16.8

130

84

15.8%

12.1

17

11

7.0%

6.62

Neoplasms benign, malignant and unspecified

54

46

5.2%

1.87

26

23

4.3%

2.41

1

1

0.6%

0.39

Nervous system disorders

166

107

12.0%

5.75

64

48

9.1%

5.94

8

6

3.8%

3.12

Psychiatric disorders

19

17

1.9%

0.66

10

10

1.9%

0.93

2

2

1.3%

0.78

Respiratory, thoracic and mediastinal disorders

226

131

14.7%

7.83

73

44

8.3%

6.78

15

10

6.4%

5.84

Skin and subcutaneous tissue disorders

260

160

18.0%

9.01

83

57

10.8%

7.71

14

11

7.0%

5.45

Surgical and medical procedures

42

38

4.3%

1.45

10

9

1.7%

0.93

1

1

0.6%

0.39

Vascular disorders

90

63

7.1%

3.12

14

14

2.6%

1.3

1

1

0.6%

0.39